MedPath
Found 472 clinical trials|View Analysis
Sort by:

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

Phase 1
Conditions
Antiphospholipid Syndrome (APS)
Bullous Pemphigoid (BP)
Dermatomyositis (DM)
Immune-mediated Necrotizing Myopathy (IMNM)
Behçet's Syndrome (BS)
Immune Thrombocytopenia (ITP)
Interventions
Drug: RAY121
First Posted Date
2024-12-09
Last Posted Date
2024-12-09
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
144
Registration Number
NCT06723106
Locations
🇦🇺

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

🇦🇺

Westmead Hospital, Sydney, New South Wales, Australia

🇦🇺

Campbelltown Public Hospital, Sydney, New South Wales, Australia

and more 49 locations

Telehealth-Based Chronic Disease Management for Type 2 Diabetes

Not yet recruiting
Conditions
Type 2 DM
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Zeng Lin, Ph. D.
Target Recruit Count
1636
Registration Number
NCT06719050

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

Phase 4
Recruiting
Conditions
Common Cold
Cough
Interventions
Drug: Robitussin Maximum Strength Cough and Chest Congestion DM
Drug: Robitussin Maximum Strength Nighttime Cough DM
First Posted Date
2024-12-04
Last Posted Date
2025-01-10
Lead Sponsor
HALEON
Target Recruit Count
260
Registration Number
NCT06716645
Locations
🇺🇸

Lindus Health Limited, New York, New York, United States

Embecta AID System in Adults With Type 2 Diabetes

Not Applicable
Withdrawn
Conditions
Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM)
Type 2 DM
T2DM With Inadequate Glycemic Control
T2DM (Type 2 Diabetes Mellitus)
T2D
T2DM
First Posted Date
2024-11-18
Last Posted Date
2024-12-16
Lead Sponsor
Embecta Corp.
Target Recruit Count
360
Registration Number
NCT06692153
Locations
🇺🇸

Stanford, Palo Alto, California, United States

🇺🇸

Diablo Research, Walnut Creek, California, United States

🇺🇸

Indiana Universtiy School of Medicine, Indianapolis, Indiana, United States

and more 6 locations

A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Phase 2
Recruiting
Conditions
SARS-CoV2
COVID-19
Interventions
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®
First Posted Date
2024-11-04
Last Posted Date
2024-11-04
Lead Sponsor
Vaxart
Target Recruit Count
10000
Registration Number
NCT06672055
Locations
🇺🇸

Pinnacle Research Group, Anniston, Alabama, United States

🇺🇸

Core Clinical Trials - Central Alabama Research LLC, Birmingham, Alabama, United States

🇺🇸

Coastal Clinical Research, Mobile, Alabama, United States

and more 142 locations

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Phase 3
Not yet recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Orforglipron
Drug: Placebo
First Posted Date
2024-11-04
Last Posted Date
2024-12-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
125
Registration Number
NCT06672549
Locations
🇺🇸

Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Velocity Clinical Research, Omaha, Nebraska, United States

🇺🇸

Vanderbilt Health One Hundred Oaks, Nashville, Tennessee, United States

and more 38 locations

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Phase 3
Recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Orforglipron
Drug: Placebo
First Posted Date
2024-11-04
Last Posted Date
2025-01-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
125
Registration Number
NCT06672939
Locations
🇺🇸

Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States

🇺🇸

Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States

🇺🇸

Stamford Therapeutics Consortium, Stamford, Connecticut, United States

and more 31 locations

Carbohydrate Quality and Its Impact on Sleep and Depression in Type 2 Diabetes

Completed
Conditions
Type 2 DM
First Posted Date
2024-10-30
Last Posted Date
2024-11-20
Lead Sponsor
Ankara Yildirim Beyazıt University
Target Recruit Count
150
Registration Number
NCT06666205
Locations
🇹🇷

Ankara Yıldırım Beyazıt University, Ankara, Turkey

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 2
Recruiting
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Drug: Maridebart Cafraglutide
Drug: Placebo
First Posted Date
2024-10-28
Last Posted Date
2025-01-03
Lead Sponsor
Amgen
Target Recruit Count
350
Registration Number
NCT06660173
Locations
🇮🇹

Universita degli Studi Gabriele D Annunzio di Chieti e Pescara, Chieti, Italy

🇵🇱

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Krakow, Poland

🇷🇴

Institutul National de Diabet si Nutritie si Boli Metabolice N C Paulescu, Bucuresti, Romania

and more 78 locations

Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomized Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Breast Cancer Screening and Diagnosis
Interventions
Diagnostic Test: magnetic resonance imaging (MRI) and digital mammography (DM)
Diagnostic Test: Contrast Enhancement Mammography
First Posted Date
2024-10-07
Last Posted Date
2024-10-07
Lead Sponsor
Azienda Unità Sanitaria Locale Reggio Emilia
Target Recruit Count
2200
Registration Number
NCT06629896
Locations
🇮🇹

Istituto in tecnologie avanzate e modelli assistenziali in oncologia - AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy/Reggio Emilia, Italy

© Copyright 2025. All Rights Reserved by MedPath